Cargando…
Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis
BACKGROUND AND OBJECTIVES: Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808353/ https://www.ncbi.nlm.nih.gov/pubmed/35105687 http://dx.doi.org/10.1212/NXI.0000000000001143 |
_version_ | 1784643870137516032 |
---|---|
author | Zabalza, Ana Arrambide, Georgina Tagliani, Paula Cárdenas-Robledo, Simón Otero-Romero, Susana Esperalba, Juliana Fernandez-Naval, Candela Trocoli Campuzano, Jesus Martínez Gallo, Mónica Castillo, Mireia Bonastre, Mercè Resina Sallés, Mireia Beltran, Jordina Carbonell-Mirabent, Pere Rodríguez-Barranco, Marta López-Maza, Samuel Melgarejo Otálora, Pedro José Ruiz-Ortiz, Mariano Pappolla, Agustin Rodríguez Acevedo, Breogán Midaglia, Luciana Vidal-Jordana, Angela Cobo-Calvo, Alvaro Tur, Carmen Galán, Ingrid Castilló, Joaquín Río, Jordi Espejo, Carmen Comabella, Manuel Nos, Carlos Sastre-Garriga, Jaume Tintore, Mar Montalban, Xavier |
author_facet | Zabalza, Ana Arrambide, Georgina Tagliani, Paula Cárdenas-Robledo, Simón Otero-Romero, Susana Esperalba, Juliana Fernandez-Naval, Candela Trocoli Campuzano, Jesus Martínez Gallo, Mónica Castillo, Mireia Bonastre, Mercè Resina Sallés, Mireia Beltran, Jordina Carbonell-Mirabent, Pere Rodríguez-Barranco, Marta López-Maza, Samuel Melgarejo Otálora, Pedro José Ruiz-Ortiz, Mariano Pappolla, Agustin Rodríguez Acevedo, Breogán Midaglia, Luciana Vidal-Jordana, Angela Cobo-Calvo, Alvaro Tur, Carmen Galán, Ingrid Castilló, Joaquín Río, Jordi Espejo, Carmen Comabella, Manuel Nos, Carlos Sastre-Garriga, Jaume Tintore, Mar Montalban, Xavier |
author_sort | Zabalza, Ana |
collection | PubMed |
description | BACKGROUND AND OBJECTIVES: Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS. METHODS: This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2. RESULTS: A total of 121 (83.45%) of 145 PwMS were seropositive, and 25/42 (59.5%) presented a cellular response up to 13.1 months after COVID-19. Anti–CD20-treated patients had lower antibody titers than those under other DMTs (p < 0.001), but severe COVID-19 and a longer time from last infusion increased the likelihood of producing a humoral response. IFN-γ levels did not differ among DMT. Five of 7 (71.4%) anti-–CD20-treated seronegative patients had a cellular response. The humoral response persisted for more than 6 months in 41/56(81.13%) PwMS. In multivariate analysis, seropositivity decreased due to anti-CD20 therapy (OR 0.08 [95% CI 0.01–0.55]) and increased in males (OR 3.59 [1.02–12.68]), whereas the cellular response decreased in those with progressive disease (OR 0.04 [0.001–0.88]). No factors were associated with antibody persistence. DISCUSSION: Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti–CD20-treated patients, even in the absence of antibodies. |
format | Online Article Text |
id | pubmed-8808353 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-88083532022-02-02 Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis Zabalza, Ana Arrambide, Georgina Tagliani, Paula Cárdenas-Robledo, Simón Otero-Romero, Susana Esperalba, Juliana Fernandez-Naval, Candela Trocoli Campuzano, Jesus Martínez Gallo, Mónica Castillo, Mireia Bonastre, Mercè Resina Sallés, Mireia Beltran, Jordina Carbonell-Mirabent, Pere Rodríguez-Barranco, Marta López-Maza, Samuel Melgarejo Otálora, Pedro José Ruiz-Ortiz, Mariano Pappolla, Agustin Rodríguez Acevedo, Breogán Midaglia, Luciana Vidal-Jordana, Angela Cobo-Calvo, Alvaro Tur, Carmen Galán, Ingrid Castilló, Joaquín Río, Jordi Espejo, Carmen Comabella, Manuel Nos, Carlos Sastre-Garriga, Jaume Tintore, Mar Montalban, Xavier Neurol Neuroimmunol Neuroinflamm Article BACKGROUND AND OBJECTIVES: Information about humoral and cellular responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and antibody persistence in convalescent (COVID-19) patients with multiple sclerosis (PwMS) is scarce. The objectives of this study were to investigate factors influencing humoral and cellular responses to SARS-CoV-2 and its persistence in convalescent COVID-19 PwMS. METHODS: This is a retrospective study of confirmed COVID-19 convalescent PwMS identified between February 2020 and May 2021 by SARS-CoV-2 antibody testing. We examined relationships between demographics, MS characteristics, disease-modifying therapy (DMT), and humoral (immunoglobulin G against spike and nucleocapsid proteins) and cellular (interferon-gamma [IFN-γ]) responses to SARS-CoV-2. RESULTS: A total of 121 (83.45%) of 145 PwMS were seropositive, and 25/42 (59.5%) presented a cellular response up to 13.1 months after COVID-19. Anti–CD20-treated patients had lower antibody titers than those under other DMTs (p < 0.001), but severe COVID-19 and a longer time from last infusion increased the likelihood of producing a humoral response. IFN-γ levels did not differ among DMT. Five of 7 (71.4%) anti-–CD20-treated seronegative patients had a cellular response. The humoral response persisted for more than 6 months in 41/56(81.13%) PwMS. In multivariate analysis, seropositivity decreased due to anti-CD20 therapy (OR 0.08 [95% CI 0.01–0.55]) and increased in males (OR 3.59 [1.02–12.68]), whereas the cellular response decreased in those with progressive disease (OR 0.04 [0.001–0.88]). No factors were associated with antibody persistence. DISCUSSION: Humoral and cellular responses to SARS-CoV-2 are present in COVID-19 convalescent PwMS up to 13.10 months after COVID-19. The humoral response decreases under anti-CD20 treatment, although the cellular response can be detected in anti–CD20-treated patients, even in the absence of antibodies. Lippincott Williams & Wilkins 2022-02-01 /pmc/articles/PMC8808353/ /pubmed/35105687 http://dx.doi.org/10.1212/NXI.0000000000001143 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Article Zabalza, Ana Arrambide, Georgina Tagliani, Paula Cárdenas-Robledo, Simón Otero-Romero, Susana Esperalba, Juliana Fernandez-Naval, Candela Trocoli Campuzano, Jesus Martínez Gallo, Mónica Castillo, Mireia Bonastre, Mercè Resina Sallés, Mireia Beltran, Jordina Carbonell-Mirabent, Pere Rodríguez-Barranco, Marta López-Maza, Samuel Melgarejo Otálora, Pedro José Ruiz-Ortiz, Mariano Pappolla, Agustin Rodríguez Acevedo, Breogán Midaglia, Luciana Vidal-Jordana, Angela Cobo-Calvo, Alvaro Tur, Carmen Galán, Ingrid Castilló, Joaquín Río, Jordi Espejo, Carmen Comabella, Manuel Nos, Carlos Sastre-Garriga, Jaume Tintore, Mar Montalban, Xavier Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis |
title | Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis |
title_full | Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis |
title_fullStr | Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis |
title_full_unstemmed | Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis |
title_short | Humoral and Cellular Responses to SARS-CoV-2 in Convalescent COVID-19 Patients With Multiple Sclerosis |
title_sort | humoral and cellular responses to sars-cov-2 in convalescent covid-19 patients with multiple sclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8808353/ https://www.ncbi.nlm.nih.gov/pubmed/35105687 http://dx.doi.org/10.1212/NXI.0000000000001143 |
work_keys_str_mv | AT zabalzaana humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT arrambidegeorgina humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT taglianipaula humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT cardenasrobledosimon humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT oteroromerosusana humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT esperalbajuliana humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT fernandeznavalcandela humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT trocolicampuzanojesus humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT martinezgallomonica humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT castillomireia humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT bonastremerce humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT resinasallesmireia humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT beltranjordina humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT carbonellmirabentpere humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT rodriguezbarrancomarta humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT lopezmazasamuel humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT melgarejootalorapedrojose humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT ruizortizmariano humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT pappollaagustin humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT rodriguezacevedobreogan humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT midaglialuciana humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT vidaljordanaangela humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT cobocalvoalvaro humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT turcarmen humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT galaningrid humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT castillojoaquin humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT riojordi humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT espejocarmen humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT comabellamanuel humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT noscarlos humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT sastregarrigajaume humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT tintoremar humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis AT montalbanxavier humoralandcellularresponsestosarscov2inconvalescentcovid19patientswithmultiplesclerosis |